Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27905531 | 0.90 | CA1 (0.51) | KDM5AEPHX2EPHX1CA1CA2 | |
| SCHEMBL29191203 | 0.86 | KDM5A (0.49) | KDM5AEPHX2EPHX1HSD11B1CYP2C9 | |
| SCHEMBL2908754 | 0.86 | KDM5A (0.49) | KDM5AEPHX2EPHX1HSD11B1CYP2C9 | |
| SCHEMBL22655447 | 0.86 | KDM5A (0.49) | KDM5AEPHX2EPHX1HSD11B1CYP2C9 | |
| SCHEMBL17082706 | 0.85 | CHRNB2 (0.42) | KDM5AEPHX2EPHX1CA1CA2 | |
| SCHEMBL13207346 | 0.84 | EPHX2 (0.45) | KDM5AEPHX2EPHX1 | |
| SCHEMBL1649898 | 0.83 | CTSK (0.61) | EPHX2EPHX1HSD11B1CYP2C9CTSK | |
| SCHEMBL12214165 | 0.83 | CTSK (0.61) | EPHX2EPHX1HSD11B1CYP2C9CTSK | |
| SCHEMBL1587352 | 0.83 | CTSK (0.61) | EPHX2EPHX1HSD11B1CYP2C9CTSK | |
| SCHEMBL17037034 | 0.83 | CA1 (0.54) | KDM5AEPHX2EPHX1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| WO-2022084741-A1 | CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-04-28 | — | — | WO | disclosed |
| CN-103153993-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2013-06-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | KDM5A 2589/4885EPHX2 1339/4885EPHX1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.